Relevium is a highly innovative life sciences company based in the West of Ireland. The core focus of the company is the development of first-in-class peptide-based therapeutics for chronic conditions. Relevium combines expertise in chemistry, engineering, and cutting edge medical science to pioneer radical solutions meeting the needs of patients. Relevium's first product is Hydrobloc-01, an injectable peptide-based gel developed to specifically treat patients with knee osteoarthritis. This patented biotherapeutic has demonstrated outstanding pre-clinical results and is due to commence Clinical Trials in 2022.